Abstract
Despite a trend of declining HIV incidence rates, up to 2 million people continue to become newly infected with HIV every year. Antiretroviral-based interventions offer optimism to achieve epidemic control, but a vaccine is needed to eliminate HIV. The path to a vaccine remains elusive because of unique features of the virus, including its ability to attack vital parts of the immune system, its high mutation rate and a little understanding on what protects a human, due to a lack of examples of a natural cure. This chapter reviews CAPRISA’s contribution to HIV vaccine research over the past decade focusing on CAPRISA’s involvement in the National Institute of Health-funded HIV Vaccine Trial Network (HVTN) Phambili trial, the first phase IIb HIV vaccine study conducted in sub-Saharan Africa, and lessons learnt during its premature closure. We then discuss ongoing Vanguard vaccine studies in preparation for the next generation of efficacy trials that CAPRISA is participating in sponsored by HVTN and Janssen Pharmaceuticals. We conclude with a synopsis of CAPRISA’s contributions to passive immunisation studies for HIV prevention.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
UNAIDS Factsheet 2015. Accessed 16 March 2016 at http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet.
Stover J, Bollinger L, Hecht R, Williams C, Roca E. The impact of an AIDS Vaccine in Developing Countries. Health Affairs 2007 Jul-Aug;26(4):1147–58.
Harmon TM, Fisher KA, McGlynn MG, Stover J, Warren MJ, Teng Y, Näveke A. Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low and Middle-Income Countries. PLoS One. 2016;11(1):e0146387.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209–20.
Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–1893.
Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. Jul 2011;11(7):507–515.
Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med. 2013;369(22):2083–92.
Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker L-G, Churchyard G, et al. The phase 2b HVTN 503/Phambili study test-of-concept HIV vaccine study, investigating a recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up. Lancet Infect Dis. 2014; 14(5):388–396.
Gray GE, de Bruyn G, Slack C, Steel G, Williamson C. Preparing developing countries for efficacy trials. Curr Opin HIV AIDS. 2006;1(4):330–335.
Gray GE, Metch B, Churchyard G, Mlisana K, Nchabeleng M, Allen M, et al. Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa? Vaccine. 2013;31(16):2089–2096.
Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.
Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643–56.
Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657–66.
Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013;155(3):531–9.
Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61.
Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182(3):289–301.
Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6(243):243ra88.
Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 1;509(7498):55–62.
Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2015;90(1):76–91.
Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, et al. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016;12(3):e1005520.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Garrett, N., Mngadi, K., Naicker, N., Morris, L. (2017). HIV Vaccine and Passive Immunity Trials. In: Abdool Karim, Q., Abdool Karim, S., Baxter, C. (eds) The CAPRISA Clinical Trials: HIV Treatment and Prevention. Springer, Cham. https://doi.org/10.1007/978-3-319-47518-9_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-47518-9_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-47517-2
Online ISBN: 978-3-319-47518-9
eBook Packages: MedicineMedicine (R0)